MG guidelines and consensus reports recommended that patients with MG be stratified into distinct subgroups, including early-onset, late-onset, thymoma, MusK low-density lipoprotein receptor-related protein 4, antibody-negative, and ocular forms of MG, helping with therapeutic decisions and prognosis evaluation. This evidence concerns the gene LRP4 and myasthenia gravis.